Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 100996717
Gene Symbol: NOTCH2NLC
NOTCH2NLC
0.010 GeneticVariation disease BEFREE These results indicate that abnormal GGC repeat expansion in the 5' region of NOTCH2NLC gene is associated with essential tremor, and provide strong evidence that essential tremor is a family of diseases with high clinical and genetic heterogeneities. 31819945 2020
Entrez Id: 4036
Gene Symbol: LRP2
LRP2
0.100 Biomarker disease BEFREE High frequency Deep brain stimulation (DBS) targeting motor thalamus is an effective therapy for essential tremor (ET). 30827864 2019
Entrez Id: 23263
Gene Symbol: MCF2L
MCF2L
0.100 Biomarker disease BEFREE OBJECTIVEPosterior subthalamic area (PSA) deep brain stimulation (DBS) targeting the zona incerta (ZI) is an emerging treatment for tremor syndromes, including Parkinson's disease (PD) and essential tremor (ET). 30875687 2019
Entrez Id: 4036
Gene Symbol: LRP2
LRP2
0.100 Biomarker disease BEFREE As the motor thalamus is the most popular DBS target for ET, and it is known that the thalamic nucleus plays a key role in relaying information about the external environment to the cerebral cortex, it is important to investigate mechanisms of thalamic DBS in the context of the cerebello-thalamo-cortical neuronal network. 31680866 2019
Entrez Id: 2521
Gene Symbol: FUS
FUS
0.100 Biomarker disease BEFREE Focused ultrasound thalamotomy (FUS-T) was recently approved for the treatment of refractory essential tremor (ET). 29579287 2019
Entrez Id: 2521
Gene Symbol: FUS
FUS
0.100 Biomarker disease BEFREE Magnetic resonance-guided focused ultrasound thalamotomy (FUS-T) is an emerging treatment for essential tremor (ET). 31690945 2019
Entrez Id: 23263
Gene Symbol: MCF2L
MCF2L
0.100 Biomarker disease BEFREE High frequency Deep brain stimulation (DBS) targeting motor thalamus is an effective therapy for essential tremor (ET). 30827864 2019
Entrez Id: 23263
Gene Symbol: MCF2L
MCF2L
0.100 Biomarker disease BEFREE As the motor thalamus is the most popular DBS target for ET, and it is known that the thalamic nucleus plays a key role in relaying information about the external environment to the cerebral cortex, it is important to investigate mechanisms of thalamic DBS in the context of the cerebello-thalamo-cortical neuronal network. 31680866 2019
Entrez Id: 4036
Gene Symbol: LRP2
LRP2
0.100 Biomarker disease BEFREE OBJECTIVEPosterior subthalamic area (PSA) deep brain stimulation (DBS) targeting the zona incerta (ZI) is an emerging treatment for tremor syndromes, including Parkinson's disease (PD) and essential tremor (ET). 30875687 2019
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.030 Biomarker disease BEFREE Therefore, CNS-derived exosomal α-synuclein in the serum may be regarded as a biomarker to identify PD from ET and HC in the early stage. 31102760 2019
Entrez Id: 6531
Gene Symbol: SLC6A3
SLC6A3
0.030 Biomarker disease BEFREE Dopamine transporter (DAT) single-photon emission tomography (SPECT) with (123)Ioflupane is a widely used diagnostic tool for patients with suspected parkinsonian syndromes, as it assists with differentiating between Parkinson's disease (PD) or atypical parkinsonisms and conditions without a presynaptic dopaminergic deficit such as essential tremor, vascular and drug-induced parkinsonisms. 31405186 2019
Entrez Id: 7431
Gene Symbol: VIM
VIM
0.030 GeneticVariation disease BEFREE OBJECTIVEThis study evaluated changes of fractional anisotropy (FA) in the ventral intermediate nucleus (VIM) of the thalamus after transcranial MR-guided focused ultrasound (TcMRgFUS) thalamotomy and their associations with clinical outcome.METHODSClinical and radiological data of 12 patients with medically refractory essential tremor (mean age 76.5 years) who underwent TcMRgFUS thalamotomy with VIM targeting were analyzed retrospectively. 30771772 2019
Entrez Id: 7431
Gene Symbol: VIM
VIM
0.030 Biomarker disease BEFREE Microstructural changes of the dentato-rubro-thalamic tract after transcranial MR guided focused ultrasound ablation of the posteroventral VIM in essential tremor. 30865338 2019
Entrez Id: 4061
Gene Symbol: LY6E
LY6E
0.020 Biomarker disease BEFREE The median percentage of empty baskets in ET patients was 1.5 times higher than controls (48.8% vs 33.5%, p < 0.001) but lower in ET than in SCA1 (59.7%, p = 0.011), SCA2 (77.5%, p = 0.003), and SCA6 (87.0%, p < 0.001). 30590599 2019
Entrez Id: 627
Gene Symbol: BDNF
BDNF
0.020 AlteredExpression disease BEFREE Compared with controls, no significant difference of BDNF and total and phosphorylated TrkB levels were observed in ET, whereas BDNF and phosphorylated TrkB levels were significantly decreased in the PD groups (p < 0.001). 30723034 2019
Entrez Id: 4287
Gene Symbol: ATXN3
ATXN3
0.020 Biomarker disease BEFREE Comparing ET with primary disorders of cerebellar degeneration (i.e., SCAs), we observed a spectrum of changes reflecting differences of degree, being generally mild in ET and SCA3 and more severe in SCA1/2/6. 31317229 2019
Entrez Id: 6311
Gene Symbol: ATXN2
ATXN2
0.020 Biomarker disease BEFREE The median percentage of empty baskets in ET patients was 1.5 times higher than controls (48.8% vs 33.5%, p < 0.001) but lower in ET than in SCA1 (59.7%, p = 0.011), SCA2 (77.5%, p = 0.003), and SCA6 (87.0%, p < 0.001). 30590599 2019
Entrez Id: 3553
Gene Symbol: IL1B
IL1B
0.010 GeneticVariation disease BEFREE However, the association might only suggest a marker of IL1B SNP associated with ET instead of the casual variant. 31092216 2019
Entrez Id: 859
Gene Symbol: CAV3
CAV3
0.010 Biomarker disease BEFREE T-CALM (Tremor-CAv3 modulation) protocol is designed to assess safety and efficacy of CX-8998, a selective modulator of the T-type calcium channel, for ET therapy. 31244760 2019
Entrez Id: 801
Gene Symbol: CALM1
CALM1
0.010 Biomarker disease BEFREE Design of T-CALM may guide future clinical studies of ET pharmacotherapies. 31244760 2019
Entrez Id: 4915
Gene Symbol: NTRK2
NTRK2
0.010 AlteredExpression disease BEFREE Peripheral BDNF/TrkB protein expression is decreased in Parkinson's disease but not in Essential tremor. 30723034 2019
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.010 Biomarker disease BEFREE These findings could lead to better knowledge of the variability in the metabolic PET profiles among patients with ET, particularly the integration of 18F-FDG PET imaging in the pretherapeutic evaluation of patients with refractory ET candidates for GKVIM. 30085092 2019
Entrez Id: 6310
Gene Symbol: ATXN1
ATXN1
0.010 GeneticVariation disease BEFREE The median percentage of empty baskets in ET patients was 1.5 times higher than controls (48.8% vs 33.5%, p < 0.001) but lower in ET than in SCA1 (59.7%, p = 0.011), SCA2 (77.5%, p = 0.003), and SCA6 (87.0%, p < 0.001). 30590599 2019
Entrez Id: 4179
Gene Symbol: CD46
CD46
0.010 Biomarker disease BEFREE Significant atrophy of bilateral MCP and ICP and bilateral cerebellar GM was observed in ET. 31161314 2019
Entrez Id: 2056
Gene Symbol: EPO
EPO
0.010 Biomarker disease BEFREE Erythropoietin ameliorates harmaline-induced essential tremor and cognition disturbances. 30974232 2019